Alexandra W. Acher1, Emily Winslow2, and Scott B. Reeder1
1University of Wisconsin School of Medicine and Public Health, Madison, WI, United States, 2Georgetown University, Washington DC, MD, United States
1University of Wisconsin School of Medicine and Public Health, Madison, WI, United States, 2Georgetown University, Washington DC, MD, United States
MRI is superior to computed tomography for
hepatic staging and surveillance of colon cancer and the clinical impact of its
use in staging and surveying stage III and IV disease should be prospectively
assessed.
Outline of stage-dependent incidence of CC,
early recurrence, and potential MRI-based treatment changes. Assuming that
early recurrence represents disease that was occult on staging imaging, the incidence of
MRI-dependent treatment changes can be estimated. For example, Stage III
patients have a reported incidence of early recurrence between 2-15%. Assuming
an MRI sensitivity of 95%, MRI liver staging at diagnosis may have detected
occult disease in 1 in 52 patients (assuming 2% early recurrence) or 1 in 7
patients (assuming 15% early recurrence).
Incidence
of CC by Stage and Incidence of Early and Late Recurrence: First column: incidence of CC by stage. Second column: incidence of early recurrence (recurrence < 12 months from curative intent surgery), by stage. For example, 50% of patients with resectable stage IV disease at diagnosis will
have early recurrence. Third column: incidence of recurrence at 5 years. For example, 60-80% of patients with resectable stage IV disease at diagnosis will recur within 5 years.